<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00884858</url>
  </required_header>
  <id_info>
    <org_study_id>HLS/MVC01/2008</org_study_id>
    <nct_id>NCT00884858</nct_id>
  </id_info>
  <brief_title>Maraviroc in Immunological Non-Responder (INR) HIV-1-infected Subjects</brief_title>
  <official_title>Use of Maraviroc (MVC) in Immunological Non-responder HIV-1-infected Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ASST Fatebenefratelli Sacco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ASST Fatebenefratelli Sacco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Suboptimal improvement in cluster of differentiation 4 (CD4) cell count is not uncommon in
      HIV-1-infected patients with suppressed plasma HIV-Ribonucleic acid (RNA) levels, and a
      decrease in CD4 cell count in patients with suppressed or low level viremia has been
      observed.

      Although the efficacy of current antiretroviral medications is well established, some
      antiviral combinations are very effective in suppressing HIV-1 load whereas do not exert any
      effect on immune reconstitution.

      Both T-cell immune activation and fibrosis of peripheral lymphoid tissue could create an
      environment in which CD4 T cell count decrease in the setting of low or suppressed plasma
      viremia is likely to occur.

      Another fascinating hypothesis, which has still to be elucidated, is that reconstitution of
      the depleted CD4 pool is blocked by an excess of glycoprotein 120 (gp120) HIV-1 protein. This
      extra-production could be counteracted by an inhibitor of the chemokine (C-C motif) receptor
      5 (CCR5) co-receptor that represents one of the major docking tools of HIV-1.

      With this in mind, the investigators would like to propose and design a pilot exploratory
      clinical trial involving a population of HIV-1-infected patients that rapidly reached a
      virologic suppression without a reconstitution of their immune system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:

        -  Evaluate the clinical efficacy of HAART intensification with MVC as treatment of HIV-1
           infection in patients with a CD4 count ≤ 200 cells/uL and/or a recovery of CD4 cells &lt;
           25% compared to the HAART initiation and with a complete and stable virologic
           suppression after 12 months of HAART. Patients could also being included if their CD4
           slope has been stable without any improvement, with an absolute value around 200
           cells/uL.

        -  Evaluate the effects of HAART intensification with MVC on the modification of
           immunologic and virologic parameters.

        -  Evaluate the tolerability of HAART intensification with MVC and the appearance of
           drug-related side effects.

      Design:

      This will be a randomised, multicenter, study that will evaluate HAART intensification with
      MVC as treatment of HIV-1 infection in patients with a CD4 count ≤ 200 cells/uL and/or a
      recovery of CD4 cells &lt; 25% compared to the HAART initiation and/or a stable CD4 slope
      without any improvement, with an absolute value around 200 cells/uL and with a complete and
      stable virologic suppression after 12 months of HAART.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD4 counts &gt; 200/uL or recovery of CD4 &gt; 25% in 2 consecutive time-points.</measure>
    <time_frame>3 and 12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Maraviroc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group will add Maraviroc to their current HAART.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects in this group will continue their current HAART without adding Maraviroc.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc</intervention_name>
    <description>Maraviroc is administered BID according to the other drugs within HAART; dosage ranges from 150 mg to 600 mg bid.</description>
    <arm_group_label>Maraviroc</arm_group_label>
    <other_name>Maraviroc brand name in the EC is Celsentri.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; or = 18

          -  HIV-Abs positivity detected by ELISA and confirmed by Western-Blot

          -  CD4 lymphocytes &lt; 200/uL and/or CD4 recovery &lt; 25% after at least 12 months of stable
             HAART

          -  HIV-RNA &lt; 50 cp/mL during the last 12 months

          -  negative pregnancy test at least 14 days prior to treatment

          -  understanding and signing the informed consent

        Exclusion Criteria:

          -  allergy/intolerance to the study drug

          -  less than 1 year from any treatment with immunomodulatory agents

          -  current OIs or neoplasms

          -  current CVD or EKG abnormalities

          -  current respiratory tract diseases or COPD

          -  treatment with steroids within 4 weeks from treatment beginning

          -  suspect of autoimmune disorder or chronic inflammatory disease

          -  active IVDUs or alcohol addicts

          -  AST and ALT &gt; 2.5 ULD

          -  serum creatinine &gt; 1.5 ULD

          -  ANC &lt; 1000/uL

          -  hemoglobin &lt; 10 g/dL

          -  platelets &lt; 75.000/uL

          -  reticulocytes &gt; 2%

          -  Karnofsky score &lt; 50
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Rusconi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universita' degli Studi di Milano, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Servizio Regionale di Immunologia Clinica e Tipizzazione Tissutale, Azienda Ospedaliero-Universitaria</name>
      <address>
        <city>Torrette di Ancona</city>
        <state>AN</state>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica di Malattie Infettive, Policlinico, Universita' degli Studi</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica di Malattie Infettive e Tropicali, Università degli Studi di Brescia, Spedali civili</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Malattie Infettive, Ospedale S. Maria Annunziata</name>
      <address>
        <city>Antella</city>
        <state>FI</state>
        <zip>50011</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica di Malattie Infettive, Ospedale San Martino</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Malattie Infettive, Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polo di Medicina Chirurgia e Odontoiatria, Polo Didattico S. Paolo</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O di Malattie Infettive, Fondazione San Raffaele del Monte Tabor</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione Clinicizzata di Malatie Infettive, Azienda Ospedaliera-Polo Universitario &quot;Luigi Sacco&quot;</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I e II Divisione Malattie Infettive, Azienda Ospedaliera-Polo Universitario Luigi Sacco</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica delle Malattie Infettive, Policlinico Universitario</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Malattie Infettive, Ospedale S. Spirito</name>
      <address>
        <city>Pescara</city>
        <state>PE</state>
        <zip>65100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica delle Malattie Infettive, Policlinico Monteluce</name>
      <address>
        <city>Perugia</city>
        <state>PG</state>
        <zip>06126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica delle Malattie Infettive, Policlinico &quot;Tor Vergata&quot;</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>III Divisione di Malattie Infettive, I.N.M.I Lazzaro Spallanzani</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IV Divisione di Malattie Infettive, INMI Lazzaro Spallanzani</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Malattie Infettive, Azienda Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinica delle Malattie Infettive, Università Cattolica del Sacro Cuore</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica delle Malattie Infettive ,Ospedale Amedeo di Savoia</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione Dipartimento Urgenze Infettivologiche ad Alta Complessità e correlate all'AIDS, Ospedale Cotugno</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2009</study_first_submitted>
  <study_first_submitted_qc>April 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2009</study_first_posted>
  <last_update_submitted>April 29, 2013</last_update_submitted>
  <last_update_submitted_qc>April 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>ASST Fatebenefratelli Sacco</investigator_affiliation>
    <investigator_full_name>Stefano Rusconi</investigator_full_name>
    <investigator_title>Researcher/Aggregate professor in infectious diseases</investigator_title>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <keyword>CD4</keyword>
  <keyword>INR</keyword>
  <keyword>HIV-1 infection</keyword>
  <keyword>extreme immunological compromission</keyword>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

